Urispas and Vesicare drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Urispas (flavoxate hydrochloride) and Vesicare (solifenacin succinate). Common drug interactions include arteriovenous fistula occlusion among females.

The phase IV clinical study analyzes what interactions people have when they take Urispas and Vesicare. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.

What is Urispas?

Urispas has active ingredients of flavoxate hydrochloride. eHealthMe is studying from 598 Urispas users. Check the latest studies of Urispas.

What is Vesicare?

Vesicare has active ingredients of solifenacin succinate. It is often used in urge incontinence. eHealthMe is studying from 30,656 Vesicare users. Check the latest studies of Vesicare.



On Jul, 27, 2026

29 people who take Urispas and Vesicare together, and have interactions are studied.

Urispas and Vesicare drug interactions.

What are the common drug interactions of Urispas and Vesicare, by gender? *:

female:

  1. Arteriovenous fistula occlusion
  2. Cough
  3. Limb injury
  4. Muscle strain (an injury to a muscle in which the muscle fibres tear)
  5. Productive cough
  6. Renal pain (kidney pain)
  7. Bladder disorder
  8. Blood creatinine increased
  9. Blood glucose increased
  10. Blood pressure increased

male:

n/a

What are the common drug interactions of Urispas and Vesicare, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Peripheral swelling
  2. Rhinorrhoea (watery mucus discharge from the nose)
  3. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  4. Thrombosis (formation of a blood clot inside a blood vessel)
  5. Blue toe syndrome (blue toe syndrome is a lack of blood flow to the toes causing a blue discoloration)
  6. Limb injury
  7. Muscle strain (an injury to a muscle in which the muscle fibres tear)
  8. Productive cough
  9. Renal pain (kidney pain)
  10. Blood creatinine increased

50-59:

n/a

60+:

  1. Bladder disorder
  2. Blood glucose increased
  3. General physical health deterioration (weak health status)
  4. Nausea (feeling of having an urge to vomit)
  5. Renal disorder (kidney disease)

What are the existing conditions these people have? *

  1. High Blood Pressure: 24 people, 82.76%
  2. Pain In Extremity: 11 people, 37.93%
  3. Indigestion: 2 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Urispas and Vesicare?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Urispas and Vesicare:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Urispas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Vesicare:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Urispas and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vesicare and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on flavoxate hydrochloride and solifenacin succinate (the active ingredients of Urispas and Vesicare, respectively), and Urispas and Vesicare (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: